Related Experiment Videos
Pharmacokinetics of amikacin in children with normal and impaired renal function
Insights
This study examined amikacin sulfate pharmacokinetics in children, finding that renal impairment significantly prolongs its serum half-life. Dosage adjustments based on creatinine clearance are crucial for maintaining therapeutic amikacin levels.
Area of Science:
- Pharmacology
- Nephrology
- Pediatrics
Background:
- Amikacin sulfate is a critical antibiotic for pediatric infections.
- Renal function significantly impacts drug clearance and efficacy.
- Understanding amikacin pharmacokinetics in children with renal impairment is essential for safe and effective dosing.
Purpose of the Study:
- To investigate the pharmacokinetics of amikacin sulfate in pediatric patients.
- To determine the relationship between renal function and amikacin serum half-life.
- To establish a basis for adjusting amikacin dosage intervals in children with impaired renal function.
Main Methods:
- Single intravenous dose of 7.5 mg/kg amikacin sulfate administered to pediatric patients.
- Pharmacokinetic analysis using a two-compartment open-kinetic model.
- Correlation of amikacin beta constant with creatinine clearance (Clcr).
Main Results:
- Amikacin exhibits a two-compartment kinetic model in children.
- Serum half-life increased from an average of 1 hour in healthy children to 14 hours in those with severe renal impairment.
- A linear relationship was found between the beta constant and creatinine clearance (beta = 0.001 + 0.005.Clcr, r = 0.818).
Conclusions:
- Renal impairment markedly alters amikacin pharmacokinetics in children.
- The established equation allows for modification of dosage intervals to maintain therapeutic amikacin concentrations.
- This pharmacokinetic data supports optimized amikacin dosing strategies in pediatric patients with varying renal function.
Abstract:
The pharmacokinetics of the antibiotic amikacin sulfate were studied in eight children with normal renal function and in ten children with varying degrees of renal impairment. All patients received a single i.v. dose of 7.5 mg/kg of the antibiotic. Amikacin follows a two-compartment open-kinetic model. The serum half-life, which in children with normal renal function has an average value of 1 hour, reached values of 14 hours in children with severe renal impairment. A lineal relationship is established between the beta constant and the creatinine clearance (Clcr) according to the equation beta = 0.001 + 0.005.Clcr, with r = 0,818. From thie equation, the dosage interval is modified to maintain the serum concentrations of the antibiotic within the therapeutic interval.